Proton therapy developer Ion Beam Applications (IBA) has posted healthy sales for 2014.
Revenues for the company grew 3.8% to 220.5 million euros ($240.7 million U.S.), compared with 212.5 million euros ($232 million) in 2013.
The company attributed the revenue boost in part to the sale of four Proteus One and two Proteus Plus systems in 2014, which represented more than 50% of the total global proton therapy market for the year.
The company's net profit for the year was 24.2 million euros ($26.4 million), a considerable improvement over the 1 million euro loss ($1.1 million) the company experienced in 2013.
